Related Experiment Video
Updated: Jul 19, 2025

Continuous Venous-Arterial Doppler Ultrasound During a Preload Challenge
Published on: January 20, 2023
Changes in Doppler-Derived Kidney Venous Flow and Adverse Cardiorenal Outcomes in Patients With Heart Failure
Faeq Husain-Syed1,2, Narayana Sarma V Singam3,4, Jason K Viehman5
1Department of Internal Medicine II University Hospital Giessen and Marburg, Justus-Liebig-University Giessen Giessen Germany.
Insights
Changes in kidney venous flow, measured by kidney venous stasis index (KVSI) and intrakidney venous-flow (IKVF) patterns, predict adverse cardiorenal outcomes in heart failure (HF) patients. Serial assessments enhance risk stratification for better clinical decisions.
Area of Science:
- Cardiology
- Nephrology
- Medical Imaging
Background:
- Heart failure (HF) management is challenged by cardiorenal complications.
- The role of Doppler-derived kidney venous flow in HF prognosis is understudied.
- Kidney venous stasis index (KVSI) and intrakidney venous-flow (IKVF) patterns are novel metrics.
Purpose of the Study:
- To investigate the association between KVSI and IKVF patterns and adverse cardiorenal outcomes in HF patients.
- To determine if changes in these venous flow parameters over time predict outcomes.
- To explore the utility of serial kidney venous flow assessment in HF risk stratification.
Main Methods:
- Observational cohort study of 216 HF inpatients with diuretic resistance and abnormal kidney function.
- Spectral kidney assessments (Doppler 1 and Doppler 2) to measure KVSI and IKVF patterns.
- Cox proportional hazard regression models to analyze associations with cardiorenal events up to 18 months.
Main Results:
- Both baseline KVSI and IKVF pattern severity were significantly associated with worsening HF or death.
- Increases in KVSI and IKVF pattern severity from baseline to follow-up independently predicted increased risk of adverse events.
- Similar associations were observed for kidney-specific outcomes.
Conclusions:
- Baseline kidney venous flow parameters (KVSI, IKVF) are significant predictors of cardiorenal events in HF.
- Serial assessment of kidney venous flow provides valuable prognostic information.
- Integrating serial kidney venous flow assessments into cardiorenal risk stratification can aid clinical decision-making for HF patients.
Abstract:
Background The impact of changes in Doppler-derived kidney venous flow in heart failure (HF) is not well studied. We aimed to investigate the association of Doppler-derived kidney venous stasis index (KVSI) and intrakidney venous-flow (IKVF) patterns with adverse cardiorenal outcomes in patients with HF. Methods and Results In this observational cohort study, consecutive inpatients with HF referred to a nephrologist because of a history of diuretic resistance and abnormal kidney function (n=216) underwent spectral kidney assessments after admission (Doppler 1) and 25 to 35 days later (Doppler 2) to identify IKVF patterns (continuous/pulsatile/biphasic/monophasic) and KVSI levels. Cox proportional hazard regression models were used to evaluate the associations between KVSI/IKVF patterns at Doppler 1 as well as changes from Doppler 1 to Doppler 2 and risk of cardiorenal events up to 18 months after admission. Worsening HF or death occurred in 126 patients. Both baseline KVSI (hazard ratio [HR], 1.49 [95% CI, 1.37-1.61] per 0.1-unit increase) and baseline IKVF pattern (HR, 2.47 [95% CI, 2.01-3.04] per 1 pattern severity increase) were significantly associated with worsening HF/death. Increases in both KVSI and IKVF pattern severity from Doppler 1 to 2 were also associated with an increased risk of worsening HF/death (HR, 3.00 [95% CI, 2.08-4.32] per 0.1-unit increase change; and HR, 6.73 [95% CI, 3.27-13.86] per 1 pattern increase in severity change, respectively). Similar results were observed for kidney outcomes. Conclusions Baseline kidney venous flow predicted adverse cardiorenal events, and inclusion of serial kidney venous flow in cardiorenal risk stratification could facilitate clinical decision-making for patients with HF. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03039959.
Related Concept Videos
Heart Failure Drugs: Diuretics
Heart Failure II: Pathophysiology
Heart Failure V: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention

